Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk AS    NOVO B   DK0060534915

NOVO NORDISK AS

(NOVO B)
  Report  
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
05/20/2019 05/21/2019 05/22/2019 05/23/2019 05/24/2019 Date
316.9(c) 318.85(c) 320.45(c) 323.9(c) 323.95(c) Last
2 323 090 1 676 028 1 698 436 2 401 196 1 927 261 Volume
+1.15% +0.62% +0.50% +1.08% +0.02% Change
More quotes
Financials (DKK)
Sales 2019 119 B
EBIT 2019 51 687 M
Net income 2019 39 050 M
Finance 2019 13 622 M
Yield 2019 2,57%
Sales 2020 127 B
EBIT 2020 55 309 M
Net income 2020 43 314 M
Finance 2020 16 082 M
Yield 2020 2,85%
P/E ratio 2019 19,75
P/E ratio 2020 17,39
EV / Sales2019 4,94x
EV / Sales2020 4,62x
Capitalization 603 B
More Financials
Company
Novo Nordisk specializes in the design, production and marketing of pharmaceutical products. Net sales break down by family of products as follows: - products for treating diabetes and obesity (84%); - hemophilia treatment products (8.6%): mainly injections of protein; - growth hormones (6.1%):... 
Sector
Pharmaceuticals
Calendar
06/09 | 10:00pmPresentation
More about the company
Surperformance© ratings of Novo Nordisk AS
Trading Rating : Investor Rating :
More Ratings
Latest news on NOVO NORDISK AS
05/20NOVO NORDISK : releases global study on obesity
AQ
05/20NOVO NORDISK A/S : - Share repurchase programme
AQ
05/11NOVO NORDISK : Becomes Longest Running Continued Title Sponsor of an American Te..
AQ
05/09NOVO NORDISK : Trading in Novo Nordisk shares by board members, executives and a..
AQ
05/07NOVO NORDISK A/S : - Share repurchase programme
AQ
05/07NOVO NORDISK A/S : purchases B shares worth DKK 2,235 million from Novo Holdings..
AQ
05/03GLOBAL MARKETS LIVE : Berkshire Hathaway, Sinclair, Tesla, Facebook…
05/03NOVO NORDISK : on track to meet 100 per cent renewables target
AQ
05/03NOVO NORDISK : Diabetes and Obesity Drugs Boost Net Profit
DJ
05/03NOVO NORDISK : operating profit increased by 14% in Danish kroner and by 8% at c..
GL
More news
Analyst Recommendations on NOVO NORDISK AS
More recommendations
Stock Trading Strategies
NOVO NORDISK A/S - 2018
Attractive timing with a long term view to go long again
BUY
More Stock Trading Analysis
Sector news : Pharmaceuticals - NEC
05/24NOVARTIS : At $2 Million, New Novartis Drug Is Priciest Ever
DJ
05/24NOVARTIS : Correction to Novartis Article
DJ
05/24NOVARTIS : FDA Approves Novartis' Piqray for Breast Cancer
DJ
05/24NOVARTIS' : Zolgensma Approved for Sale in U.S. to Treat SMA in Infants at $2.12..
DJ
05/24SAMSUNG ELECTRONICS : South Korea orders further arrests at Samsung Electronics ..
RE
More sector news : Pharmaceuticals - NEC
Chart NOVO NORDISK AS
Duration : Period :
Novo Nordisk AS Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVO NORDISK AS
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 27
Average target price 341  DKK
Spread / Average Target 5,3%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Helge Lund Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK AS8.74%90 543
JOHNSON & JOHNSON8.32%368 655
PFIZER-3.96%233 239
ROCHE HOLDING LTD.11.42%233 096
NOVARTIS17.44%219 832
MERCK AND COMPANY6.23%208 984